Skip to main content

Table 7 Rank for 28 patients at the ten positions available, when all outcomes were included in the analysis

From: Rapid methods including network meta-analysis to produce evidence in clinical decision support: a decision analysis

  Rank 1 Rank 2 Rank 3 Rank 4 Rank 5 Rank 6 Rank 7 Rank 8 Rank 9 Rank 10
PLB 0 2 0 0 0 1 6 5 2 12
OLZ 6 10 5 1 1 1 4 0 0 0
LIT 0 0 2 20 4 2 0 0 0 0
RISlai 0 0 0 0 0 2 6 4 8 8
LAM 5 3 0 4 11 4 1 0 0 0
LITVAL 6 5 10 1 4 2 0 0 0 0
QTP 11 7 7 0 1 1 0 1 0 0
VAL 0 0 3 2 4 11 4 4 0 0
IMI 0 1 1 0 0 1 3 8 10 4
LITIMI 0 0 0 0 3 3 4 6 8 4
  1. PLB placebo, OLZ olanzapine, LIT lithium, RISlai risperidone LAI, LAM lamotrigine, LITVAL lithium + valproate, QTP quetiapine, VAL valproate, IMI imipramine, LITIMI lithium + imipramine